has also demonstrated that an apparently acquired disease may be based fundamentally on a congenital defect as well as incidentally starting off a new chapter in human genetics.
The second way in which drug sensitivity hemolytic antemia can be produced, which is much rarer, is based on an auto-immune mechanism, and can be looked upon as an example of true hypersensitivity. Its recognition stems from the observations of Harris (1954, 1956) in America on a patient who was treated for schistosomiasis with an antimony-containing drug. The patient had received a course of the drug ten years before without apparent incident, but when the second course was started he developed signs of intolerance by the fifth day and was found to be anmmic and to have developed hemoglobinuria. He had in fact hemolytic anmmia and the direct antiglobulin test was positive. Harris was subsequently able to show that the patient had developed an antibody which acted on his red cells, and normal red cells also, but only in the presence of the drug. It seems likely that the patient had formed an antibody against a drugred-cell complex and that this then reacted against the patient's own red cells in vivo, presumably being bound to the cells through the intermediacy of the drug. Since Harris's pioneer studies, a similar mechanism has been demonstrated in the case of quinidine (Freedman et al. 1956 ), quinine (Muirhead et al. 1958), phenacetin and PAS (MacGibbon et al. 1960 ), antazoline (Dausset & Bergerot-Blondel 1961 , Mallassenet et al. 1960 , and salicylazosulphapyridine (Shinton & Wilson 1960) .
We have investigated two of these cases at the Postgraduate Medical School of London; in one patient phenacetin was involved, in the other PAS. The history of the patient who was hypersensitive to phenacetin is of exceptional interest:
Case report A woman, aged 38, was admitted to hospital in April 1958 suffering from jaundice and oliguria of unknown origin. Severe oliguria and azotemia persisted but diuresis commenced on the tenth day and she made a good recovery. In October 1958, six months later, she became seriously ill once more after taking four analgesic tablets for incipient coryza, again with jaundice and oliguria. This time she was admitted into Hammersmith Hospital where she once more recovered on conservative treatment. The tablets she had taken were found to contain phenacetin and this led to a series of serological investigations the result of which paralleled those reported by Harris. In particular, her serum sensitized normal red cells to agglutination by antiglobulin serum in the presence of phenacetin at a concentration of 2-5 ,ig/100 ml upwards. Two known metabolic products of phenacetin, paracetamol and paraphenetidine, also produced positive reactions.
Phenacetin may have many virtues, but it is without doubt remarkable in being capable of producing hxemolytic anemia in three ways: (1) In normal therapeutic dosage in apparently normal (not enzyme-deficient) subjects, (2) in (presumably) very small dosage in enzyme-deficient subjects, and (3) in rare instances, as described above, by an auto-immune mechanism.
In summary, it is obvious that the drug-induced hemolytic anemias are still important clinical problems and that they are likely to remain so as long as new drugs are invented. The discovery of enzyme deficiency of red cellswhich can be demonstrated in the laboratory by comparatively simple techniqueshas provided an explanation for a type of racial susceptibility to drugs. Knowledge of the possibility of this deficiency should put the physician on his guard when treating members of the negro and Jewish races, in particular. Haemolysis resulting from the immune mechanism of hypersensitivity is much rarer, but it is of more than laboratory interest only, for in individual patients it can lead to a serious catastrophe. 111, 1916 The Immunological Basis of Purpura due to Drug Hypersensitivity by J F Ackroyd DSC MB MRCP (London) Purpura due to drug hypersensitivity may be thrombocytopenic or nonthrombocytopenic. In the latter case, the drug appears to affect only the capillaries. In thrombocytopenic cases, the capillaries and platelets are affected but, by patch testing, the vascular lesion can be produced independently of any demonstrable effect on the platelets. The mechanisms by which drug hypersensitivity causes purpura are discussed below.
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Symposium on Drug Sensitization
The following summary is based on the author's observations on cases of thrombocytopenic purpura due to apronal (allyl-isopropylacetyl-carbamide) (Ackroyd 1949a (Ackroyd , b, c, 1951 (Ackroyd , 1958 , antazoline (2(N-phenyl-N-benzyl-aminomethyl) imidazoline) (Ackroyd 1958, 1960 and  unpublished observations), quinine (Ackroyd, unpublished observations), and phenolphthalein (Ackroyd & Mowbray, unpublished observations) , and on cases of nonthrombocytopenic purpura due to carbromal (diethyl-bromo-acetylcarbamide). The findings reported below in cases of thrombocytopenic purpura due to drug hypersensitivity have been confirmed in full, or in part, by other workers in cases due to a large variety of different drugs (see Ackroyd 1962) . In particular, they have been confirmed in great detail by Bolton (1956) and Shulman (1958a, b, c) in cases of thrombocytopenic purpura due to quinidine, and by Kissmeyer-Nielsen (1956) in a case of thrombocytopenic purpura due to quinine.
The Cause ofthe Low Platelet Count in Cases ofThrombocytopenic Purpura Due to Drug Hypersensitivity
In almost all the cases so far investigated, the addition of the drug to the patient's plasma, after recovery, has caused platelet agglutination, and sometimes also, platelet lysis. If the patient still has thrombocytopenia, the addition of platelets from compatible normal blood will usually enable platelet agglutination and lysis to be demonstrated.
Platelet agglutination occurs in the absence of complement; platelet lysis, when it occurs, requires the presence of complement.
Platelet agglutination and lysis are dependent on an abnormal factor in the plasma and serum of the patient. They are not due to any abnormality of the patient's platelets. This can readily be shown by experiments in which normal platelets are suspended in the patient's serum, and the patient's platelets in normal serum. Apronal causes platelet lysis and complement fixation when normal platelets are suspended in the sera of apronal-sensitive patients but not when the patient's platelets are su'spended in normal sera. This has also been shown to be true for cases of thrombocytopenic purpura due to other drugs. It may therefore be concluded that four factors are required for platelet lysis by a drug in the blood of a sensitized patient. These are: (I) platelets, (2) the serum of a sensitized patient, (3) the drug, and (4) complement. As a working hypothesis it may be postulated that the drug combines with the platelet and in so doing modifies it sufficiently to render it auto-antigenic; in other words, that the drug acts as a hapten conferring antigenic properties on the platelet. This concept is shown schematically in Fig 1. The drugplatelet antigen may then be assumed to stimulate antibody formation, the antibody being the serum factor referred to above. This hypothesis explains the serological findings, and also accounts for the clinical observation that these patients develop thrombocytopenia only when they take the drug; for it is only when the patient takes the drug that the platelets become antigenic and can be destroyed by the antibody with resultant thrombocytopenia. The Nature ofthe Drug-platelet Combination During the course of the experiments described above, it was noticed that if the platelets were washed in saline after being allowed to react with the patient's serum and the drug in the absence of complement, both the antibody and the drug (apronal) were removed from the platelets. This observation suggested a simple method by which it might be possible to discover the role of apronal in the reaction causing platelet agglutination and lysis and complement fixation. It was assumed that, as apronal was so loosely attached to platelets, it might be possible to remove it from combination with platelets and antibody by dialysis. This was found to be so. It was also found that if platelets which had been suspended in the serum of a sensitive patient in the presence of apronal, but in the absence of complement, were washed, not in saline but in a saturated solution of apronal in saline, then the antibody remained in contact with the platelets. Platelets which had been treated in this way were then dialysed against saline. Examination of the preparation after dialysis showed that not only had dialysis removed the apronal but the removal of the apronal had caused dissociation of platelets and antibody; for, when the preparation was centrifuged, the antibody was found in the supernatant fluid and caused complement fixation if further platelets and drug were added. These experiments, which were performed both with the platelets of apronalsensitive patients and of normal individuals, seem to demonstrate clearly that apronal acts as a link between the platelet and the antibody because, if the drug is removed, the platelets separate from the antibody. They also seem to provide considerable support for the hypothesis outlined above and shown schematically in Fig 1, namely that the drug combines with the platelets and, acting as a hapten, alters the surface of the platelet in such a way that it becomes antigenic. When the drug is removed by dialysis, the platelets are no longer antigenic and, for this reason, separate from the antibody.
The Nature ofthe Antibody Electrophoresis of the antibody prepared in one of the dialysis experiments described above showed it to be almost entirely y-globulin. This was confirmed by fractionating the sera of patients who had recovered from apronal purpura. It was found that the y-globulin fraction was the only one which fixed complement in the presence of platelets and the drug.
Precipitate Formation by Drugs in the Sera of Patients with Thrombocytopenic Purpura Due
to Drug Hypersensitivity The addition of a drug to the plasma or serum of a patient who has, or who has recovered from, thrombocytopenic purpura due to that drug may cause immune precipitate formation. This phenomenon is rare and its significance is unknown. It has been seen only twice by the author: once in a case due to antazoline (see Ackroyd 1955, Fig 1) and once in a case due to phenolphthalein. Apart from these, only three other examples have been found in the literature: one was a case due to apronal (Miescher & Miescher 1952) , one due to quinidine (Lopez Garcia & Sainz de la Maza 1951), and one to chlorothiazide (Nordqvist et al. 1959 ). In the case due to chlorothiazide, precipitate formation was described as 'very weak'. The addition of the appropriate drug to platelet-rich plasma from the patients who were sensitive to antazoline and phenolphthalein respectively, not only caused precipitate formation but also platelet agglutination and lysis. The addition of the drug to suspensions of platelets in the patients' sera caused precipitate formation and complement fixation. In the absence of platelets, the addition of phenolphthalein to the serum of the patient who was sensitive to this drug caused precipitate formation but did not cause complement fixation, whereas the addition of antazoline to the serum of the antazoline-sensitive patient in the absence of platelets caused both precipitate formation and complement fixation. Initially, the precipitin fixed all the available complement, but, in course of time, as the precipitin titre fell in successive samples of the patient's fresh serum, complement fixation became less complete and then the addition of platelets to the serum increased the degree of complement fixation caused by the drug. It seems probable, therefore, that both platelet lysis and precipitate formation by antazoline in this patient's plasma and serum are complementfixing reactions.
The Relationship ofthe Precipitin to the Platelet-lytic Antibody Two experiments were performed in an endeavour to discover whether precipitate formation and platelet lysis by antazoline are different manifestations of the activity of the same antibody or whether they are caused by two different antibodies.
In the first experiment, the drug was added to the serum and when precipitate formation was complete, the precipitate was removed by centrifugation. Addition of platelets and the drug to the serum after removal of the precipitate did not cause fixation of added complement, suggesting that the removal of the precipitate had removed the platelet-lytic antibody.
In the second experiment, platelets and antazoline were added to the patient's serum and the platelets were removed by centrifugation before a visible precipitate had had time to form. More antazoline was then added but no precipitate formed.
These experiments show that removing the precipitate removes the platelet-lytic factor, and removing platelets, which presumably have the platelet-lytic factor adsorbed on them, removes the precipitin. It seems probable, therefore, that platelet lysis and precipitate formation are manifestations of the activity of the same antibody. If this is so, then the simplest explanation for these phenomena might be that platelet lysis results from the action of the platelet-lytic antibody on intact platelets whereas precipitate formation results from the action of the same antibody on platelet break-down products liberated into the serum during coagulation.
To investigate this possibility, two preparations were made of the patient's citrated platelet-rich plasma. The platelets were removed from one sample by centrifugation and the platelet-'free' supernatant plasma was aspirated. Samples of the platelet-rich and platelet-'free' plasma were then clotted with calcium chloride, and the serum from each was separated. Antazoline was added to each preparation. The precipitin titre in the serum prepared from the platelet-'free' plasma was identical with the titre in serum made from the platelet-rich plasma. Moreover, there was no difference in the bulk of the precipitates in the two preparations. It therefore seems clear that precipitate formation is independent of the presence of platelet breakdown products in the serum. Some factor concerned with precipitate formation is labile and the precipitin titres in the sera of both the antazoline-sensitive and the phenol-phthalein-sensitive patients quickly fell to very low levels, even when the sera were stored at -20°C. After the initial rapid fall in titre, very slight precipitate formation coiuld be demonstrated for several months in serum from the antazoline-sensitive patient, but in serum from the phenolphthalein-sensitive patient, precipitate formation could not be demonstrated after storage for five and a half weeks. Because of this rapid deterioration, and also because the precipitin titres of successive samples of fresh serum from both patients fell about as quickly as the titres of their stored sera, it has not proved possible to analyse the phenomenon of precipitate formation by drugs any further. Since precipitate formation is not dependent on the presence of platelet protein, it seems clear that it must involve one or more of the serum proteins. Moreover, since the available evidonce suggests that platelet lysis and precipitate formation are due to the action of the same antibody, and as platelet lysis in cases without precipitate formation has been shown probably to be due to an antibody acting on platelets rendered antigenic by combination with the drug, it seems likely that precipitate formation is due to the action of the platelet-lytic antibody on plasma protein rendered antigenic by union with the drug. The possibility that one antibody might react with these two antigensthe platelet antigen and the protein antigenis perhaps not unlikely because both antigens have the same hapten determinant group, namely, the drug. This concept is shown schematically in The Relationship ofPrecipitate Formation to the Different Drugs which have Caused Thrombocytopenic Purpura As stated above, precipitate formation appears to have been reported only in 5 cases of thrombocytopenic purpura. These were due to quinidine (Lopez Garcia & Sainz de la Maza 1951), apronal (Miescher & Miescher 1952) , chlorothiazide (Nordqvist et al. 1959) , antazoline (Ackroyd 1958, and unpublished observations) , and phenolphthalein (Ackroyd & Mowbray, unpublished observations) . Occasional cases of thrombocytopenic purpura due to antazoline and to chlorothiazide, and numerous cases due to quinidine and to apronal have been described in which pre-cipitate formation was not observed; it would, therefore, seem that precipitate formation is due to an unusual reaction on the part of the patient rather than to the nature of the causative drug.
The Capillary Lesion
Patch testing: Both in cases of thrombocytopenic purpura, and nonthrombocytopenic purpura due to drugs, if the patient is highly sensitive to the drug, the application of the drug to the patient's skin may cause a local increase in capillary fragility and sometimes the appearance of purpuric hmmorrhages in the area of skin to which the drug is applied (see Ackroyd 1960, Plates 4 and 8 A & B) . In cases of thrombocytopenic purpura, there may be a fall in the platelet count if a sufficient amount of the drug is absorbed through the skin, but in many cases there is no change in the platelet count, a finding which suggests that even in cases of thrombocytopenic purpura, the capillary lesion may be independent of any effect of the drug on the platelets. In nonthrombocytopenic cases, the drug presumably affects only the capillaries.
The Histological Appearances of the Purpuric Rash The histological appearances of the skin in an area of purpura caused by patch testing a patient who had recovered from thrombocytopenic purpura due to apronal (see Ackroyd 1960 , Plate 8 C & D) and one who had recovered from nonthrombocytopenic purpura due to carbromal (see Ackroyd 1960, Plate 5) have been studied by the author. In each, the most prominent feature was a perivascular inflammatory reaction around the small vessels of the dermis. The endothelial cells appeared normal even in areas of capillary hkmorrhage. The inflammatory cells were mainly polymorphonuclear leucocytes, lymphocytes and macrophages. Essentially similar findings have been reported in skin not subjected to patch testing but taken at the height of the hemorrhagic episode from an area of purpura, in a case of nonthrombocytopenic purpura due to menthol (Highstein & Zeligman 1951) and in a case of thrombocytopenic purpura due to glyceryl trinitrate (Shmushkovich & Davis 1955) .
The Mechanism by which Patients Become
Sensitized to Drugs in such a Way as to Cause Purpura The most striking fact about purpura due to drug hypersensitivity is that, although purpura has been caused by a large number of different drugs, yet only a very small proportion of patients taking any of these drugs ever develop purpura. It has been shown above that in case of thrombocytopenic purpura, the drug probably com-bines with platelets and, acting as a hapten, renders them auto-antigenic. Apronal combines with the platelets of normal individuals when these are in contact with serum (Ackroyd 1958) or with traces of plasma (Dausset 1958) from the same individual. If this combination is formed in the blood of all patients taking the drug and if it is, in fact, antigenic, then it must presumably be a very weak antigen since it stimulates antibody formation (and consequently causes purpura) so seldom. Alternatively, it is conceivable that there is some immunological peculiarity in the platelets of patients who develop purpura which renders the drug-platelet combination antigenic only in such individuals. This seems unlikely because the dialysis experiments referred to above, which were performed with platelets from normal individuals and from patients who had recovered from apronal purpura, showed that the drug dialysed equally readily from each, suggesting that the drug-platelet combination is as labile in patients who have become sensitized as it is in normal individuals. If this is so, then the very lability of the drug-platelet complex would suggest that it is indeed probably a very weak antigen, because such a labile compound will not often remain in contact with the antibody-forming tissues long enough to stimulate antibody formation. It seems possible, therefore, that the lability of the union may explain why so few of those taking the drug develop purpura, for only those whose antibodyforming mechanisms are stimulated by this labile antigen will develop the antibody.
Observations on cases of thrombocytopenic purpura due to quinine (Kissmeyer-Nielsen 1956) and quinidine (Bolton 1956 , Shulman 1958a suggest that the drug-platelet complex is as labile in these conditions as it is in cases of thrombocytopenic purpura due to apronal. It would seem likely, therefore, that if the above hypothesis is true for cases of purpura due to apronal, it will prove to be true for cases of thrombocytopenic purpura due t6 other drugs.
One difficulty in accepting the hypothesis that the drug acts as a hapten lies in the fact that neither platelet lysis, precipitate formation nor complement fixation is inhibited by high concentrations of the causative drug. In systems involving artificially conjugated haptens, the antigen-antibody reaction can be inhibited by excess of hapten, because the hapten combines with the antibody and so prevents interaction of antibody with the hapten-protein conjugate. Landsteiner (1947) did find, with some of his artificially conjugated haptens, that high concentrations of the hapten were required to produce inhibition because the hapten-antibody combination had a considerable tendency to dissociate. The dialysis experiments described above show that the com-bination of the drug with platelets, and also with antibody, can be separated by dialysis, and it may be, therefore, that the lability ofthe drug-antibody combination is a factor causing the failure of large concentrations of drugs to inhibit platelet agglutination and lysis and complement fixation. Kabat (1962) in discussing this problem, has pointed out that it may need a thousand molecules in solution to inhibit the action of a single artificially conjugated hapten molecule. However, the concentrations of drugs used to demonstrate platelet agglutination and lysis have sometimes been so great as to imply a vastly greater excess than this. For example, Day et al. (1958) were able to demonstrate platelet agglutination and lysis in the plasma of a patient who was sensitive to novobiocin, using a final concentration of 025 % of the drug. This must represent such an enormous excess in terms of molecules per platelet, that it would seem that some explanation other than dissociation of the drug-antibody complex may be necessary to account for the failure of excess of the drug to inhibit platelet agglutination and lysis and complement fixation. Evidence that very high concentrations of the drug are required to inactivate all the available antibody has come from some observations made on the case of thrombocytopenic purpura due to antazoline referred to above. On two occasions, when this patient developed thrombocytopenia and purpura in response to test dosing, precipitate formation could be demonstrated in serum taken at the time the thrombocytopenia developed. This, however, required the addition of the drug; no precipitate developed on incubating the serum alone. The second of these test-dosing experiments was undertaken at a time when complement fixation and precipitate formation could readily be demonstrated by adding the drug to the patient's serum in vitro. The administration of the drug in increasing doses was continued for four days without any change being observed in the platelet count, although throughout this period the antibody could be demonstrated by adding the drug to the patient's serum in vitro. On the fifth day a further dose was given and the patient developed thrombocytopenic purpura but, as stated above, the addition of the drug to the patient's serum still caused precipitate formation. A similar need for very large amounts of a drug is sometimes seen when an attempt is made to demonstrate sensitivity by test dosing. Although a positive response to test dosing may be observed in response to the administration of very small doses of a drug, it not infrequently happens that very large doses are required. A most striking example of this was reported by Wurzel & Mayock (1953) . Their patient, who had recovered from an attack of thrombocytopenia with hama-temesis due to para-aminosalicylic acid, received a course of test doses totalling 10 g in two days before a significant fall in the platelet count was observed. Six days later, a dose of 7 0 g over a period of three days was required to produce a fall in her platelet count.
Perhaps the simplest explanation of the high concentrations of the drug that may be required in in vitro and in vivo experiments is that these high concentrations are needed to force the drug into combination with the platelets to form the antigen. In order to explain why these concentrations do not inhibit the reaction, it would seem necessary further to postulate that the antibody is incapable of reacting with the drug alone and can react only with the drug-platelet conjugate or, in addition, in cases where precipitate formation occurs, with a conjugate of the drug with plasma protein.
The vascular lesion remains to be explained. By patch testing patients who have recovered from thrombocytopenic purpura due to drug hypersensitivity, localized purpura can be produced in the absence of thrombocytopenia. Since, therefore, the drug can cause damage to platelets and capillary endothelium, it seems reasonable to suggest that both are affected by the same mechanism and that in such patients the drug may combine with the vascular endothelium to form a further antigen which then reacts with the antibody which causes platelet lysis and also, in rare cases, precipitate formation. Some experiments performed with sera from two patients who had recovered from thrombocytopenic purpura due to apronal have produced results which suggest that a reaction between the platelet-lytic apronal antibody, apronal and vascular endothelial cells may take place, but so far the results have not been sufficiently clear cut to permit any definite conclusions to be drawn from them (Ackroyd, unpublished observations) . Bolton (1956) and Shulman (1958b) , who also tried to demonstrate such a reaction, were unsuccessful and the possibility can, therefore, only be regarded as an interesting speculation. The inflammatory reaction seen around the skin vessels in cases of purpura due to drug hypersensitivity is not confined to this condition and a similar picture has been observed in a wide variety of skin diseases. It is, nevertheless, temnpting to suggest that this perivascular inflammatory reaction may be the result of an antigen-antibody reaction occurring in the vessel wall, and that, in thrombocytopenic cases, this results from the antibody which causes platelet lysis reacting with endothelial cells rendered antigenic by union with the drug. In nonthrombocytopenic cases, it may be postulated that the capillary fragility and perivascular inflammatory reaction are due to an antibody acting only on endothelial cells rendered antigenic by union with the drug. It must, however, be emphasized that these suggestions are purely speculative and that neither in thrombocytopenic, nor in nonthrombocytopenic purpura due to drug hypersensitivity has an anti-endothelial antibody been demonstrated.
To summarize, the following hypothesis may be put forward to explain the occurrence of purpura due to drug hypersensitivity. It must be emphasized that this hypothesis is tentative and much further work remains to be done before it can be confirmed or refuted:
(1) Purpura is an occasional complication of treatment with a large number of different drugs.
(2) In many, if not all of those taking any of these drugs which are potential causes of thrombocytopenic purpura, the drug forms a very labile combination with the platelets.
(3) This drug-platelet combination is potentially antigenic, the drug acting as a hapten. Because the combination is so labile, it rarely remains in contact with the antibody-forming tissues long enough to stimulate antibody formation.
(4) Once the antibody has formed, the patient develops thrombocytopenia whenever he takes the drug. This is because the platelets combine with the drug which renders them antigenic. Lysis of these platelets by antibody then causes thrombocytopenia.
(5) Very rarely, the drug also causes immune precipitate formation. The significance of this is unknown. It is independent of the presence of platelet breakdown products liberated into the serum during coagulation. Precipitate formation appears to be due to the action of the same antibody which causes platelet lysis. It probably results from the action of this antibody on plasma protein rendered antigenic by union with the drug.
(6) Very little is known of the nature of the vascular lesion in purpura due to drug hypersensitivity. Even in thrombocytopenic cases, the capillary lesion appears to be independent of any effect on the platelets. It is suggested that the increase in capillary fragility and the perivascular inflammatory reaction seen around the small superficial skin vessels in these cases are due to the antibody which causes platelet lysis acting on vascular endothelial cells rendered antigenic by union with the drug. Such a reaction has not, however, been demonstrated. with certainty in vitro. In nonthrombocytopenic cases, the vascu-lar lesion appears to be the only cause of the purpura. Histologically, the skin shows a perivascular inflammatory reaction which closely resembles that seen in thrombocytopenic cases. It is possible that the increased capillary fragility and the perivascular inflammatory reaction are due to the action of an antibody which acts only on endothelial cells rendered antigenic by union with the drug. No such antibody has, however, been demonstrated.
Drug Agranulocytosis and Marrow Aplasia by M C G Israels MD FRCP (Manchester)
Agranulocytosis Agranulocytosis occurs clinically in two forms, acute and chronic. It is the acute form that is most often associated with sensitivity to drugs. Chronic neutropenia is far from common and in most patients no definite cause can be found, but at the Royal Infirmary, Manchester, we have seen a few patients who had been taking drugs for long periods at some time and the presumably toxic effect had persisted.
Acute agranulocytosis was originally traced to amidopyrine. Several workers, Dr Wilkinson and myself included (Israels & Wilkinson 1937), were able to show that in a sensitive subject a minute dose of amidopyrine was sufficient to cause disappearance of the neutrophils from the blood also in a few hours. The neutrophils usually come back into the blood again within a few hours.
Amidopyrine is hardly ever used to-day, but a few proprietary mixtures still contain it: these drugs can easily be avoided. Since the time of amidopyrine many other drugs have been implicated; one textbook gives a list of 50. Fortunately many are doubtful reports about isolated cases, and the number of drugs that are really troublesome is in fact small.
After amidopyrine, the early sulphonamides, especially sulphapyridine, were responsible for a few cases. The next group to be troublesome was the thiouracils used as antithyroid drugs. Only some of the reported cases were fatal; many of the patients recovered when the drug was stopped. It was while studying thiouracil agranulocytosis that we found that examination of the bone marrow gave a good guide to prognosis. If there were still healthy myelocytes present, the patient usually recovered; on the other hand if the marrow was hypoplastic, most of the cells being lymphocytes, plasma and reticulum cells, the prognosis was very bad. Thiouracil agranulocytosis is rarely seen to-day; we use methyl thiouracit in much smaller doses than when it was first introduced. Carbimazole is usually considered to be the safest of the antithyroid drugs, but in the last six years, three reports of fatal agranulocytosis have appeared in British journals; all were acute cases and all the patients were having the recommended dose of 30 mg daily (Shaw 1955 , Burrell 1956 , Tait 1957 .
The latest drugs to cause agranulocytosis are the tranquillizers. Chlorpromazine, promazine, imipramine, meprobamate and pecazine have all been the subject of reports of agranulocytosis, not always fatal. Schick & Virks (1956) reviewed 21 cases due to chlorpromazine reported in the literature up to 1956: 13 had recovered. Many of the cases due to tranquillizers have been in patients who were in mental hospitals for the treatment of severe depression and were receiving considerable doses of the drugs. Gore & Biezanek (1956) gave pecazine to a depressed woman of 35; she had 75 mg daily for fourteen days, then 150 mg daily for four weeks. The drug was then stopped because a routine blood count showed 3,000 white cells per c.mm with 53 % polymorphs. Ten days later the W.B.C. numbered 850 with no polymorphs; the patient had sore throat, feverand headache and pharyngeal ulcers appeared. She recovered quite quickly. Cook et al. (1957) used promazine in a similar patient. She received 300 mg daily for two days and then 600 mg daily. On the twenty-fifth day she complained of sorethroat; on the twenty-seventh she had pyrexia and cervical adenitis; the W.B.C. was 1,900 and no polymorphs could be found. The sternal marrow showed only fatty tissue with no cellular areas. However, treated with penicillin, corticotrophin.
